asco@alo33:161487 JSONTXT

Background: The mCRPC patient population is heterogeneous, and clinical outcomes are influenced by clinical presentation and treatment history. Using the Prostate Cancer Registry NCT02236637 database, e assessed hether the subset of mCRPC patients ith metastatic M status at initial diagnosis represents patients ith different clinical and disease characteristics in a real-life context. Methods: We report findings from the first 1323 consecutive patients in the Prostate Cancer Registry, a 3-year, prospective, observational study of the routine management of 3000 patients ith mCRPC across Europe. Results: Of the 1323 patients analyzed, 549 had distant metastases at initial diagnosis M1, 41.5 percent , 526 did not M0, 39.8 percent , and 248 ere not evaluable Mx, 18.7 percent . Conclusions: In this sample of 1323 men ith mCRPC in routine practice, a higher percentage ith M1 at diagnosis presented ith aggressive and extended disease at mCRPC. M status at initial diagnosis may be a critical indicator of future treatment and prognosis in mCRPC, and follo-up of these patients over the course of the study ill clarify ho these differences and subsequent treatment may affect clinical outcomes. ltcaption class=mtgabstract-table-title Characteristics.ltth class=border-bottom align-left rospan=2 At initial diagnosisltth class=border-bottom-broken colspan=3 M stageM0M1MxPatients, n526549248Mean SD patient age, years73.6 7.2 70.6 8.6 74.2 7.7 75 years, n percent 241 45.8 187 34.1 128 51.6 Gleason score 8-10, n percent 218 44.6 331 66.5 118 52.7 Prior to study entryYears from diagnosis to CRPC, median range 6.2 0-20 2.4 0-16 5.5 0-29 Years from first M diagnosis to study entry, median range 2.0 0-15 2.5 0-13 1.9 0-11 Radical prostatectomy, n percent 204 38.8 31 5.6 69 27.8 Prostate radiotherapy, n percent 300 57.0 49 8.9 84 33.9 At study entryProstate-specific antigen, ngmL, median range 45.9 0.0-5910.0 61.7 0.0-10710.0 46.1 0.0-2530.5 Bone lesions, n percent a049 13.5 8 1.9 14 7.9 1-20208 57.5 228 55.2 110 61.8 2049 13.5 75 18.2 21 11.8 ECOG PS, n percent a0-1436 87.2 426 83.4 201 87.4 251 10.2 71 13.9 21 9.1 Any analgesic therapy, n percent 192 36.5 274 49.9 111 44.8 ltfn id=TF-161487-001-1 ltp class=mtgabstract-table-fn SD, standard deviation. a Some patients not evaluable.lttable-rap-foot ,J Clin Oncol 34, 2016 suppl; abstr 5024 00:00.0,Genitourinary Prostate Cancer